BioCryst/$BCRX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About BioCryst
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Ticker
$BCRX
Sector
Primary listing
Employees
580
Headquarters
Website
BioCryst Metrics
BasicAdvanced
$1.5B
-
-$0.05
0.90
-
Price and volume
Market cap
$1.5B
Beta
0.9
52-week high
$11.31
52-week low
$6.00
Average daily volume
6.6M
Financial strength
Current ratio
1.87
Quick ratio
1.599
Long term debt to equity
-165.934
Total debt to equity
-175.267
Interest coverage (TTM)
0.87%
Profitability
EBITDA (TTM)
80.422
Gross margin (TTM)
68.43%
Net profit margin (TTM)
-1.46%
Operating margin (TTM)
12.90%
Effective tax rate (TTM)
-32.67%
Revenue per employee (TTM)
$1,030,000
Management effectiveness
Return on assets (TTM)
10.31%
Return on equity (TTM)
2.05%
Valuation
Price to revenue (TTM)
2.439
Price to book
-3.8
Price to tangible book (TTM)
-3.8
Price to free cash flow (TTM)
30.571
Free cash flow yield (TTM)
3.27%
Free cash flow per share (TTM)
0.229
Growth
Revenue change (TTM)
45.38%
Earnings per share change (TTM)
-92.49%
3-year revenue growth (CAGR)
36.00%
10-year revenue growth (CAGR)
28.44%
3-year earnings per share growth (CAGR)
-64.89%
10-year earnings per share growth (CAGR)
-21.41%
What the Analysts think about BioCryst
Analyst ratings (Buy, Hold, Sell) for BioCryst stock.
BioCryst Financial Performance
Revenues and expenses
BioCryst Earnings Performance
Company profitability
BioCryst News
AllArticlesVideos
Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS
Business Wire1 month ago
BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'
Benzinga1 month ago
BioCryst to buy Astria Therapeutics in $700 million deal
Reuters1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioCryst stock?
BioCryst (BCRX) has a market cap of $1.5B as of November 20, 2025.
What is the P/E ratio for BioCryst stock?
The price to earnings (P/E) ratio for BioCryst (BCRX) stock is 0 as of November 20, 2025.
Does BioCryst stock pay dividends?
No, BioCryst (BCRX) stock does not pay dividends to its shareholders as of November 20, 2025.
When is the next BioCryst dividend payment date?
BioCryst (BCRX) stock does not pay dividends to its shareholders.
What is the beta indicator for BioCryst?
BioCryst (BCRX) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.